Key result
The SUR1 alanine 1369 C-allele variant was more frequent in thyrotoxic periodic paralysis patients than in thyrotoxicosis patients without paralysis (61.1% vs 34.4%; OR 3.42, P=0.039).
Why the study?
Is the SUR1 Ala1369Ser variant associated with thyrotoxic periodic paralysis in patients with thyrotoxicosis?
Case-Control (n=68)
Is the SUR1 Ala1369Ser variant associated with thyrotoxic periodic paralysis in patients with thyrotoxicosis?
Odds Ratio: 3.42
Absolute Event Rate: 61.1% vs 34.4%
p-value: p=0.039
The SUR1 alanine 1369 variant is associated with susceptibility to thyrotoxic periodic paralysis, potentially linking hyperinsulinemia to the condition's pathophysiology.
No takes yet. Share an insight, caveat, or question.
Supports SUR1 variant as TPP risk marker in thyrotoxicosis; hypothesis-generating, needs replication before clinical use.
Rolim et al. (2014) conducted a case-control in Thyrotoxic periodic paralysis (n=68). SUR1 Ala1369Ser C-allele variant vs. Thyrotoxicosis without paralysis was evaluated on Frequency of the alanine 1369 C-allele (OR 3.42, p=0.039). The SUR1 alanine 1369 C-allele variant was more frequent in thyrotoxic periodic paralysis patients than in thyrotoxicosis patients without paralysis (61.1% vs 34.4%; OR 3.42, P=0.039).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: